Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Past Issues
    • Accepted Articles
    • Email Alerts
    • RSS
    • Terms of Use
  • About PDA JPST
    • JPST Editors and Editorial Board
    • About/Vision/Mission
    • Paper of the Year
  • Author & Reviewer Resources
    • Author Resources / Submit
    • Reviewer Resources
  • JPST Access and Subscriptions
    • PDA Members
    • Institutional Subscriptions
    • Nonmember Access
  • Support
    • Join PDA
    • Contact
    • Feedback
    • Advertising
    • CiteTrack
  • .
    • Visit PDA
    • PDA Letter
    • Technical Reports
    • news uPDATe
    • Bookstore

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
PDA Journal of Pharmaceutical Science and Technology
  • .
    • Visit PDA
    • PDA Letter
    • Technical Reports
    • news uPDATe
    • Bookstore
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
PDA Journal of Pharmaceutical Science and Technology

Advanced Search

  • Home
  • Content
    • Current Issue
    • Past Issues
    • Accepted Articles
    • Email Alerts
    • RSS
    • Terms of Use
  • About PDA JPST
    • JPST Editors and Editorial Board
    • About/Vision/Mission
    • Paper of the Year
  • Author & Reviewer Resources
    • Author Resources / Submit
    • Reviewer Resources
  • JPST Access and Subscriptions
    • PDA Members
    • Institutional Subscriptions
    • Nonmember Access
  • Support
    • Join PDA
    • Contact
    • Feedback
    • Advertising
    • CiteTrack
  • Follow pda on Twitter
  • Visit PDA on LinkedIn
  • Visit pda on Facebook
Research ArticleTECHNOLOGY/APPLICATIONS

Pharmaceutical Development of a Parenteral Formulation of the Investigational Anticancer Drug Clanfenur

Jantine D. Jonkman-De Vries, Bart J. F. Van Den Bemt, Wim W. Ten Bokkel-Huinink, Willy J. M. Underberg, J. Jantina Kettenes-Van Den Bosch, Roland E. C. Henrar, Auke Bult and Jos H. Beijnen
PDA Journal of Pharmaceutical Science and Technology March 1997, 51 (2) 89-95;
Jantine D. Jonkman-De Vries
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bart J. F. Van Den Bemt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wim W. Ten Bokkel-Huinink
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Willy J. M. Underberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Jantina Kettenes-Van Den Bosch
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roland E. C. Henrar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Auke Bult
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jos H. Beijnen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • References
  • Info & Metrics
  • PDF
Loading

Abstract

A stable parenteral dosage form for the investigational cytotoxic drug clanfenur was designed, and the bulk drug was characterized by its nuclear magnetic resonance, mass spectrometry, infrared, and ultraviolet spectra. The 1H and 13C spectra show clanfenur to be a mixture of two stereoisomers. Because of poor solubility in aqueous solution and precipitation in co-solvent, surfactant, or emulsion systems, a two-pump infusion system was developed for intravenous administration. Clanfenur, solubilized in a Cremophor EL/ethanol (1:1, w/v) solution (concentration, 15 mg/mL), can be simultaneously infused with 5% dextrose infusion fluid. Total doses of up to 1,680 mg of clanfenur (and 56 g of Cremophor EL) theoretically can be administered to patients over a 6-hour period. From accelerated stability testing of clanfenur in the Cremophor EL/ethanol (1:1, w/v) formulation, a shelf life of 3.5 years at 4°C and of 4 months at 25°C is calculated.

  • Received February 5, 1996.
  • Accepted November 4, 1996.
  • Copyright © Parenteral Drug Association. All rights reserved.

PDA members receive access to all articles published in the current year and previous volume year. Institutional subscribers received access to all content. Log in below to receive access to this article if you are either of these.  

If you are neither or you are a PDA member trying to access an article outside of your membership license, then you must purchase access to this article (below). If you do not have a username or password for JPST, you will be required to create an account prior to purchasing. 

Full issue PDFs are for PDA members only.

Note to pda.org users

The PDA and PDA bookstore websites (www.pda.org and www.pda.org/bookstore) are separate websites from the PDA JPST website. When you first join PDA, your initial UserID and Password are sent to HighWirePress to create your PDA JPST account. Subsequent UserrID and Password changes required at the PDA websites will not pass on to PDA JPST and vice versa. If you forget your PDA JPST UserID and/or Password, you can request help to retrieve UserID and reset Password below.

Log in using your username and password

Forgot your user name or password?

Log in through your institution

You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

patientACCESS

patientACCESS - Patients desiring access to articles

Full issue PDFs are for PDA members only. You can join PDA at www.pda.org. 

PreviousNext
Back to top

In This Issue

PDA Journal of Pharmaceutical Science and Technology
Vol. 51, Issue 2
March-April 1997
  • Table of Contents
  • Index by Author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on PDA Journal of Pharmaceutical Science and Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Pharmaceutical Development of a Parenteral Formulation of the Investigational Anticancer Drug Clanfenur
(Your Name) has sent you a message from PDA Journal of Pharmaceutical Science and Technology
(Your Name) thought you would like to see the PDA Journal of Pharmaceutical Science and Technology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
4 + 7 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Pharmaceutical Development of a Parenteral Formulation of the Investigational Anticancer Drug Clanfenur
Jantine D. Jonkman-De Vries, Bart J. F. Van Den Bemt, Wim W. Ten Bokkel-Huinink, Willy J. M. Underberg, J. Jantina Kettenes-Van Den Bosch, Roland E. C. Henrar, Auke Bult, Jos H. Beijnen
PDA Journal of Pharmaceutical Science and Technology Mar 1997, 51 (2) 89-95;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Pharmaceutical Development of a Parenteral Formulation of the Investigational Anticancer Drug Clanfenur
Jantine D. Jonkman-De Vries, Bart J. F. Van Den Bemt, Wim W. Ten Bokkel-Huinink, Willy J. M. Underberg, J. Jantina Kettenes-Van Den Bosch, Roland E. C. Henrar, Auke Bult, Jos H. Beijnen
PDA Journal of Pharmaceutical Science and Technology Mar 1997, 51 (2) 89-95;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Evaluation of Steam Sterilization Processes: Comparing Calculations Using Temperature Data and Biointegrator Reduction Data and Calculation of Theoretical Temperature Difference
  • Optimization of the Drug Solution Preparation Process for a Production-Scale Crossflow Ultrafiltration System
  • Bacterial Adhesion: Considerations Within A Risk-Based Approach To Cleaning Validation
Show more Technology/Applications

Similar Articles

Readers

  • About
  • Table of Content Alerts/Other Alerts
  • Subscriptions
  • Terms of Use
  • Contact Editors

Author/Reviewer Information

  • Author Resources
  • Submit Manuscript
  • Reviewers
  • Contact Editors

Parenteral Drug Association, Inc.

  • About
  • Advertising/Sponsorships
  • Events
  • PDA Bookstore
  • Press Releases

© 2025 PDA Journal of Pharmaceutical Science and Technology Print ISSN: 1079-7440  Digital ISSN: 1948-2124

Powered by HighWire